Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime ...(d Conference Call Evotec has schedule...),Health

Evotec has scheduled an R&D Update in London at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) today which will be broadcast live on the internet. Evotec will also present details on this positive Phase II study in insomnia at that meeting.

For those who prefer to listen to the presentation via phone, please

dial:

From Europe: +49-(0)-69-5007-1308 (Germany)

+44-(0)-20-7806-1956 (UK)

From the US: +1-718-354-1388

Pass Code: 2793143

The on-demand version of the webcast will be available on our website:

http://www.evotec.com - Investors - Webcasts.

Notes to the Editor

Study design

This US, multi-centre, randomised, double-blind, placebo-controlled, parallel group design trial was designed to evaluate the hypnotic efficacy of EVT 201 in the treatment of primary insomnia in elderly patients with daytime sleepiness. Patients were screened for entry into the study and the eligibility criteria included: age greater than or equal to 65 years; a diagnosis of primary insomnia according to DSM (Diagnostic and Statistical Manual of Mental Disorders) IV; mean TST 240-410 minutes inclusive determined during two consecutive nights polysomnography (PSG) evaluation; mean MSLT greater than or equal to 4 and less than or equal to 16. Patients were randomised to receive EVT 201 1.5 mg or EVT 201 2.5 mg or placebo for seven consecutive nights. PSG data was collected for two nights at Screening and on nights 1, 6 and 7 during the Treatment Period. The primary endpoint of this trial was to assess Total Sleep Time (TST) determined by PSG. The secondary endpoints included additional PSG-based measures such as latency to persistent sleep, wake after sleep onset and effects on sleep architecture. In addition, subjective sleep quality and quantity were assessed, along with the Profile of Mood State (POMS). Daytime function was assessed objectiv
'/>"/>